1621673-53-7
1621673-53-7 結(jié)構(gòu)式
基本信息
4-[[([1,1'-Biphenyl]-4-ylmethyl)thio]methyl]-N-(hexylsulfonyl)benzamide
Benzamide, 4-[[([1,1'-biphenyl]-4-ylmethyl)thio]methyl]-N-(hexylsulfonyl)-
inhibit,anti-diabetic,leptin,ZO-1,LPS,insulin,phosphorylated,KY-226,Akt,KY226,anti-obesity,PTP1B,Phosphatase,neurons,Inhibitor,KY 226
物理化學(xué)性質(zhì)
常見問題列表
| Target | Value |
|
PTP1B
(Cell-free assay) | 0.28 μM |
In human hepatoma-derived cells (HepG2), KY-226 (0.3-10 μM) increases the phosphorylated insulin receptor (pIR) produced by insulin.
KY-226 (1 μM; 24 hours; bEnd.3 cells) treatment rescues lipopolysaccharide-induced reduction of mRNA and protein levels of ZO-1. KY-226 treatment restores phosphorylation of pAkt (T308) and its downstream target forkhead box protein O1 (FoxO1) (S256) in bEnd.3 cells.
Western Blot Analysis
| Cell Line: | bEnd.3 cells stimulated with LPS |
| Concentration: | 1 μM |
| Incubation Time: | 24 hours |
| Result: | Rescued lipopolysaccharide-induced reduction of mRNA and protein levels of ZO-1. |
KY-226 (10-30 mg/kg/day; oral administration; daily; for 4 weeks; male
db/db
mice) treatment significantly reduces plasma glucose and triglyceride levels as well as hemoglobin A1c values without increasing body weight gain.
KY-226 attenuates plasma glucose elevations in the oral glucose tolerance test. KY-226 also increases pIR and phosphorylated Akt in the liver and femoral muscle.
| Animal Model: | Male db/db mice (8-11 weeks old) |
| Dosage: | 10 mg/kg and 30 mg/kg |
| Administration: | Oral administration; daily; for 4 weeks |
| Result: | Significantly reduced plasma glucose and triglyceride levels as well as hemoglobin A1c values without increasing body weight gain. |